German China

UK: Disruptive 2D Mass Spectrometry

Spin-Out of Warwick University Raises Seed Investment for New 2DMS Technology

| Editor: Alexander Stark

Disruptive 2DMS technique is to make pharmaceutical research and food safety testing more accurate, more efficient, and at least 10 times quicker. (symbolic image)
Gallery: 1 image
Disruptive 2DMS technique is to make pharmaceutical research and food safety testing more accurate, more efficient, and at least 10 times quicker. (symbolic image) (Source: Pixabay / Pixabay)

Verdel Instruments — a spin-out company of the University of Warwick — has developed new disruptive two-dimensional mass spectrometry (2DMS) technology. The company now raised seed investment of over $ 290,000 from Longwall Ventures and Innovate UK. Their new technology is set to make pharmaceutical research and food safety testing more accurate, at least ten times quicker than at present, and allows higher throughput analyses.

Warwick/UK — Designed by researchers, the innovation from Verdel is the first benchtop instrument with 2DMS capability. The new technique makes the advanced 2DMS process accessible outside academia for the first time. It quickly and efficiently delivers high quality structural analysis and sequencing of every component in a complex mixture at the same time.

This disruptive 2DMS technology employs electric pulses to manipulate ions in a linear ion trap before fragmentation to enable parallel acquisition of mass spectra, which operates in combination with UV laser-based fragmentation and a fast mass analyser such as a time-of-flight. This data independent analysis (DIA) technique offers better specificity, sensitivity, and speed in sample analysis than current techniques in routine use, the developers claim.

Symphogen to Use Thermo Fisher's Mass Spectrometry Technology to Analyze Complex Therapeutic Proteins

USA: New Therapies for Cancer Patients

Symphogen to Use Thermo Fisher's Mass Spectrometry Technology to Analyze Complex Therapeutic Proteins

12/11/2018 - Thermo Fisher Scientific and Symphogen, a clinical-stage antibody oncology-focused company, have entered into a two-year collaborative partnership to deliver validated, platform workflows for simplified characterization and quality monitoring of complex therapeutic proteins. read...

Currently, complex samples run on liquid chromatography-mass spectrometry instruments used in the pharmaceutical industry require long run times, sometimes in the region of 90 minutes. If anomalies are found in the data, the run can be extended by an additional 180 minutes. With 2DMS, only a single 20-minute analysis is required. The new technique enables researchers to analyse multiple complex samples in one go, with all the data produced in parallel — something that has previously been impossible.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 45955470 / Laborpraxis Worldwide)